Diabetes Care Unit, UOSD Diabetologia, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Nutr Metab Cardiovasc Dis. 2022 Oct;32(10):2392-2398. doi: 10.1016/j.numecd.2022.07.003. Epub 2022 Jul 16.
The use of technology offers recognized benefits to persons with diabetes. The aim of this study was to evaluate the organization of healthcare facilities, the composition of the diabetes team, and the use of Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring (CGM) in Italy.
Diabetes care centers were asked to complete a web survey based on information collected in 2018. Sixty-one pediatric and 243 adult centers participated in the survey, accounting for 507,386 patients, mostly with type 2 diabetes (86.4%). Fifty-three percent of pediatric centers and 11% of adult centers reported a team composed of diabetologists, nurses, and psychologists. Overall, 13,204 patients (2.6%) were using CSII (95% with type 1 diabetes), and 28,936 (5.7%), were using CGM (74% with type 1 diabetes). When stratifying for the type of diabetes, 24% and 40.8% of patients with type 1 were using CSII and CGM, respectively, whereas low use of technology was reported for patients with type 2 and women with gestational diabetes. The percentage of adult and pediatric patients with type 1 diabetes on CSII and CGM was respectively 21% and 32%, and 35% and 57%.
The spread of CGM and CSII increased in Italy between 2013 and 2018. However, the percentage of users is still lower than what is expected based on clinical indications for use of technology. The inadequate number of professionals in the diabetes care team and insufficient economic resources are relevant barriers to disseminating technology for diabetes management.
技术的应用为糖尿病患者带来了公认的益处。本研究旨在评估意大利医疗保健机构的组织、糖尿病团队的组成以及连续皮下胰岛素输注(CSII)和连续血糖监测(CGM)的使用情况。
要求糖尿病护理中心根据 2018 年收集的信息完成一项网络调查。61 家儿科和 243 家成人中心参与了这项调查,共涉及 507386 名患者,其中大多数为 2 型糖尿病患者(86.4%)。53%的儿科中心和 11%的成人中心报告其团队由糖尿病专家、护士和心理学家组成。总体而言,有 13204 名患者(2.6%)正在使用 CSII(95%为 1 型糖尿病患者),28936 名患者(5.7%)正在使用 CGM(74%为 1 型糖尿病患者)。按糖尿病类型分层时,分别有 24%和 40.8%的 1 型糖尿病患者使用 CSII 和 CGM,而 2 型糖尿病患者和妊娠糖尿病女性的技术使用率较低。1 型糖尿病成人和儿科患者使用 CSII 和 CGM 的比例分别为 21%和 32%,35%和 57%。
2013 年至 2018 年间,意大利 CGM 和 CSII 的使用有所增加。然而,使用率仍低于基于技术使用临床适应证的预期。糖尿病护理团队中专业人员数量不足和经济资源有限是推广糖尿病管理技术的相关障碍。